RxDoctor Payments Data

Brian Blackwell, MD

Internal Medicine · New Canton, VANPI 1447238738

Payments from drug & device makers

$310in general payments, 2019–2025

Across 16 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$110
  • Gilead$45
  • Alkermes, Inc.$38
  • GSK$27
  • Teva Pharmaceuticals USA, Inc.$24
  • Novo Nordisk$21
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$310 in reported general payments places this provider in the 60th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$162,653
Medicare patients
1,027
Services billed
3,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban140$108,354
JardianceEmpagliflozin64$76,905
JanuviaSitagliptin Phosphate57$68,590
TrulicityDulaglutide40$49,336
Invega SustennaPaliperidone Palmitate12$35,804
FarxigaDapagliflozin Propanediol26$24,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$19,789
Soliqua 100-33Insulin Glargine/Lixisenatide12$13,518
XareltoRivaroxaban13$12,293
EntrestoSacubitril/Valsartan12$11,389
Spiriva HandihalerTiotropium Bromide15$9,205
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$8,366
NovologInsulin Aspart12$7,282
Advair HfaFluticasone Propion/Salmeterol20$7,078
SymbicortBudesonide/Formoterol Fumarate21$6,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Paxlovid$110$114,876214 claims
MerckJanuvia$13$68,59057 claims
Lilly USA, LLCTrulicity$17$49,33640 claims
GSKTrelegy Ellipta, Shingrix$27$23,51241 claims
Novo NordiskNovolog$21$7,28212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in New Canton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →